Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 5/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.51 |
| ▸ | SIK1 | P57059 | 1/20 | 0.50 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.50 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.50 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084851 | 0.88 | FGFR1 (0.52) | FGFR2FGFR1FGFR4FGFR3KDR | |
| SCHEMBL4084253 | 0.87 | MAPK14 (0.62) | FGFR2FGFR1FGFR4FGFR3PAK1 | |
| SCHEMBL4088372 | 0.85 | PAK1 (0.49) | FGFR2FGFR1FGFR4FGFR3KDR | |
| SCHEMBL4083975 | 0.85 | LCK (0.54) | FGFR2FGFR1FGFR4FGFR3PAK1 | |
| SCHEMBL13849305 | 0.84 | PAK1 (0.47) | FGFR2FGFR1PAK1RIPK2ACVR1 | |
| SCHEMBL4094734 | 0.84 | PAK1 (0.51) | FGFR2FGFR1FGFR4FGFR3KDR | |
| SCHEMBL4084250 | 0.84 | TNK2 (0.47) | FGFR2FGFR1FGFR4FGFR3KDR | |
| SCHEMBL4084454 | 0.82 | LCK (0.49) | FGFR1PAK1SIK1SIK2SIK3 | |
| SCHEMBL4094645 | 0.81 | LCK (0.49) | FGFR1PAK1SIK1SIK2SIK3 | |
| SCHEMBL4091041 | 0.81 | PAK1 (0.44) | FGFR2FGFR1PAK1RIPK2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | claimed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | TLR1, TPMT, NOD1 | FGFR2 2524/4885FGFR1 1184/4885FGFR4 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.